Vitestro, the pioneering autonomous blood drawing company, today announced that it has raised $22 million (€20 million) funding to accelerate commercialization of its innovative robotic blood drawing device.
This brings its total funding raised to $50 million (€46 million) from both equity investments and grant funding.
Vitestro Secures Oversubscribed Funding Round to Drive European Expansion and U.S. Market Entry
Led by returning investor Sonder Capital and newcomer NYBC Ventures, alongside Invest-NL, the European Innovation Council Fund (EIC Fund), and existing private investors, the oversubscribed funding round will propel Vitestro’s European commercialization and facilitate its organizational expansion into the U.S. market.